Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Phase 1 Interventional

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

NCT06736418
View directory record Official record
Conditions
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
225Ac-ABD147
Drug
Lead sponsor
Abdera Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

NCT03719690
View directory record Official record
Conditions
HRAS Gene Mutation, HNSCC
Interventions
Tipifarnib, HRAS Detection Assay
Drug · Device
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Not applicable Interventional

Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer

NCT05830838
View directory record Official record
Conditions
Malignant Prostate Neoplasm
Interventions
Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

NCT01611155
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
venlafaxine, placebo, questionnaire administration, quality-of-life assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Safety and Performance Study of the INGEVITY Lead

NCT01688843
View directory record Official record
Conditions
Bradycardia, Sinus Node Dysfunction
Interventions
INGEVITY lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
44
States / cities
Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Communication in Older Cancer Patients and Their Caregivers

NCT02107443
View directory record Official record
Conditions
Adult Solid Neoplasm, Lymphoma
Interventions
Geriatric Assessment Summary, Geriatric Assessment Targeted Recommendations, Geriatric Assessment (GA)
Behavioral
Lead sponsor
Supriya Mohile
Other
Eligibility
70 Years and older
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
19
States / cities
Duarte, California • Newark, Delaware • Honolulu, Hawaii + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?

NCT00434915
View directory record Official record
Conditions
Aging
Interventions
DHEA
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 30, 2026, 10:25 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity

NCT01327976
View directory record Official record
Conditions
Obesity
Interventions
vBloc (Active Device), Sham (Non-active Device)
Device
Lead sponsor
ReShape Lifesciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

NCT02572817
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
High-titer anti-influenza plasma, Low-titer anti-influenza plasma
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Weeks and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational

Pilot to Assess DBE as a Rescue Technique for Failed PEJ

NCT01057940
View directory record Official record
Conditions
Patients Who Have Failed Conventional DPEJ Placement
Interventions
DBE PEJ placement
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

NCT01498289
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
Interventions
FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
508
States / cities
Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

NCT01383343
View directory record Official record
Conditions
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Sorafenib Tosylate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 3

NCT02854033
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

NCT01960348
View directory record Official record
Conditions
TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

Latiglutenase as a Treatment for Celiac Disease

NCT03585478
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Immunogenics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 30, 2026, 10:25 AM EDT
Recruiting No phase listed Observational

Parkinson's Foundation PD GENEration Genetic Registry

NCT04994015
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Lab Assay for seven genetic variants for Parkinson's Disease
Device
Lead sponsor
Parkinson's Foundation
Other
Eligibility
18 Years and older
Enrollment
35,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Esophageal Absorption in EoE

NCT02314455
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
D-xylose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Natural Language Processing and Quality Assessment in Primary Care

NCT01023243
View directory record Official record
Conditions
Diabetes
Interventions
Brochure: Care of the Feet for Those at Risk, Quality Survey: foot exam, tobacco and aspirin use
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT02968108
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

NCT02094118
View directory record Official record
Conditions
Blood Transfusion Complications
Interventions
Point-of-care washed red blood cell transfusion., Standard of care red blood cell transfusion.
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 30, 2026, 10:25 AM EDT